Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis used for the purpose of supporting a patient's weak or deformed arm to enable and improve functional activities of daily living, ADLs, in the home and community. Its products are designed to help restore function in individuals with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, rehabilitation hospitals, and through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
Phone+1-617-9969058
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees45
Next Earnings Date8/6/2019 (Estimated)
OptionableNot Optionable
Myomo (NYSEAMERICAN:MYO) Frequently Asked Questions
What is Myomo's stock symbol?
Myomo trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MYO."
How were Myomo's earnings last quarter?
Myomo Inc (NYSEAMERICAN:MYO) issued its quarterly earnings data on Monday, May, 13th. The company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.03. The company had revenue of $0.83 million for the quarter, compared to the consensus estimate of $0.86 million. View Myomo's Earnings History.
When is Myomo's next earnings date?
What price target have analysts set for MYO?
2 equities research analysts have issued 12 month target prices for Myomo's shares. Their predictions range from $12.00 to $12.00. On average, they expect Myomo's share price to reach $12.00 in the next year. This suggests a possible upside of 1,225.8% from the stock's current price. View Analyst Price Targets for Myomo.
What is the consensus analysts' recommendation for Myomo?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myomo.
Has Myomo been receiving favorable news coverage?
News headlines about MYO stock have been trending positive recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Myomo earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days.
Are investors shorting Myomo?
Myomo saw a decline in short interest in April. As of April 15th, there was short interest totalling 345,013 shares, a decline of 14.5% from the March 29th total of 403,527 shares. Based on an average daily trading volume, of 88,769 shares, the short-interest ratio is presently 3.9 days. Approximately 2.3% of the shares of the company are short sold. View Myomo's Current Options Chain.
Who are some of Myomo's key competitors?
Some companies that are related to Myomo include Resonance Health (RHT), Protech Home Medical (PHM), Osprey Medical (OSP), Electromed (ELMD), Universal Biosensors (UBI), Surgical Innovations Group (SUN), Avacta Group (AVCT), LBT Innovations (LBT), Oventus Medical (OVN), EMvision Medical Devices (EMV), GI Dynamics (GID), Inspiration Healthcare Group (IHC), Total Brain (TTB), Azure Healthcare (AZV) and Anteo Diagnostics (ADO).
What other stocks do shareholders of Myomo own?
Who are Myomo's key executives?
Myomo's management team includes the folowing people:
- Mr. Paul R. Gudonis, Chairman, Pres & CEO (Age 64)
- Mr. Jonathan Naft, VP & GM (Age 54)
- Mr. David A. Henry, Chief Financial Officer (Age 58)
- Mr. Clifford J. Conneighton, Chief Marketing Officer (Age 69)
- Dr. Brandon Green DO, BOCP, Chief Medical Officer (Age 72)
Who are Myomo's major shareholders?
Myomo's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include ICM Asset Management Inc. WA (1.56%), Jane Street Group LLC (0.49%) and Renaissance Technologies LLC (0.24%).
Which major investors are buying Myomo stock?
MYO stock was purchased by a variety of institutional investors in the last quarter, including ICM Asset Management Inc. WA, Jane Street Group LLC and Renaissance Technologies LLC.
How do I buy shares of Myomo?
Shares of MYO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myomo's stock price today?
One share of MYO stock can currently be purchased for approximately $0.9051.
How big of a company is Myomo?
Myomo has a market capitalization of $15.47 million. Myomo employs 45 workers across the globe.
What is Myomo's official website?
How can I contact Myomo?
Myomo's mailing address is One Broadway, 14Th Floor, CAMBRIDGE, MA 02142, United States. The company can be reached via phone at +1-617-9969058.
MarketBeat Community Rating for Myomo (NYSEAMERICAN MYO)
MarketBeat's community ratings are surveys of what our community members think about Myomo and other stocks. Vote "Outperform" if you believe MYO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYO will underperform the S&P 500 over the long term. You may vote once every thirty days.
